Positron emission tomography for radiation treatment planning

Strahlentherapie und Onkologie

Volumn 181, Issue 8, 2005, Pages 483-499

  Grosu, Anca Ligia ^a   Piert, Morand ^a   Weber, Wolfgang A ^a   Jeremic, Branislav ^a   Picchio, Maria ^a,b   Schratzenstaller, Ulrich ^a   Zimmermann, Frank B ^a   Schwaiger, Markus ^a   Molls, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Biological imaging; Biological target volume; PET; Radiation treatment planning

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' DEOXY 3' FLUOROTHYMIDINE F 18; ACETIC ACID C 11; ALPHA METHYLTYROSINE I 123; AZOMYCIN ARABINOSIDE F 18; CHOLINE C 11; CHOLINE F 18; EARLY GROWTH RESPONSE FACTOR 1; FLOXURIDINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; IODOAZOMYCIN ARABINOSIDE I 123; LIPOCORTIN 5; METHIONINE; METHIONINE C 11; METHYLTHIOSEMICARBAZONE CU 60; O 2 FLUOROETHYLTYROSINE F 18; OXIME DERIVATIVE; PRODRUG; TRACER; UNCLASSIFIED DRUG; UPENAZIME TC 99M; VITRONECTIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; ATELECTASIS; BRAIN CANCER; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CELL PROLIFERATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM CANCER; GENE EXPRESSION; GLIOMA; HEAD AND NECK CANCER; HUMAN; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHOMA; MENINGIOMA; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIATION FIELD; REVIEW; SARCOMA; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION; TUMOR VOLUME; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; VALIDATION PROCESS; VIRAL GENE THERAPY; X RAY;

BRAIN NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASMS; NEOPLASMS, UNKNOWN PRIMARY; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; UTERINE CERVICAL NEOPLASMS;

EID: 23044509962     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-005-1422-7     Document Type: Review

References (148)

1. Adams S, Baum RP, Stuckensen T, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255-60.
2. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988;62:1074-8.
3. Assar O, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: role and usefulness of FDG-PET in locating occult primary tumors. Radiology 1999;210:177-81.
4. Barthel H, Cleij MC, Collingridge DR, et al. 3′-deoxy-3′- [18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8.
5. Belhocine T, Steinmetz N, Li C, et al. The imaging of apoptosis with the radiolabeled annexin V: optimal timing for clinical feasibility. Technol Cancer Res Treat 2004;3:23-32.
6. Benchaou M, Lehmann W, Slosman DO, et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol (Stockh) 1996;116:332-5.
7. Bergström M, Collins VP, Ehrin E, et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 1983;7:1062-6.
8. Bohuslavizki KH, Klutmann S, Kroger S, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000;41:816-22.
9. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in NSCLC. Int J Radiat Oncol Biol Phys 2004;59:78-86.
10. Braun V, Dempf S, Weller R, et al. Cranial neuronavigation with direct integration of (11)C methionine positron emission tomography (PET) data results of a pilot study in 32 surgical cases. Acta Neurochir (Wien) 2002;144:777-82, discussion 782.
11. Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300-9.
12. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171-82.
13. Chapman JD, Bradley JD, Eary JF, et al. Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. Int J Radiat Oncol Biol Phys 2003;55:294-301.
14. Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:1024-35.
15. Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003;57:853-63.
16. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002;223:91-7.
17. Cook GJ, Fogelman I. Tumor hypoxia: the role of nuclear medicine. Eur J Nucl Med 1998;25:335-7.
18. Dehdashti F, Grigsby PW, Mintun MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233-8.
19. De Jong IJ, Pruim J, Elsinga PH, et al. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002;42:18-23.
20. DiChiro G. Positron emission tomography using F-18 fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1986;22:360-71.
21. Effert PJ, Bares R, Handt S, et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996;155:994-8.
22. Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002;62:51-60.
23. Ericson K, Lilja A, Bergstrom M, et al. Positron emission tomography with ((11C)methyl-L-methionine, (11C)D-glucose and (68Ga)EDTA in supratentorial tumors. J Comput Assist Tomogr 1985;9:683-9.
24. Fischbein NJ, AAssar OS, Caputo GR, et al. Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent sguamous cell carcinoma of the head and neck. AJNR Am J Neuroradiol 1998;19:1189-96.
25. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361-8.
26. Gagel B, Reinartz P, Dimartino E, et al. p0(2) polarography versus positron emission tomography (18F-fluoromisonidazole, 18F-2-Fluoro-2′- deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004;180:616-22.
27. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.
28. Giraud P, Grahek D, Montravers F, et al. CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 2001;49:1249-57.
29. Goldman S, Levivier M, Pirotte B, et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 1996;78:1098-106.
30. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003;139:879-92.
31. Graves EE, Nelson SJ, Vigneron DB, et al. A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas. Neurosurgery 2000;46:319-26, discussion 326-18.
32. Greven KM, Keyes JW Jr, Williams DW 3rd, et al. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer 1999;86:114-8.
33. Grigsby PW, Siegel BA, Dehdashti F, et al. Posttherapy surveillance monitoring of cervical cancer by FDG PET. Int J Radiat Oncol Biol Phys 2003;55:907-13.
34. Gross MW, Weber WA, Feldmann HJ, et al. The value of F-18- fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 1998;41:989-95.
35. Grosu AL, Feldmann H, Dick S, et al. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys 2002;54:842-54.
36. Grosu AL, Lachner R, Wiedenmann, N et al. Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. Int J Radiat Oncol Biol Phys 2003;56:1450-63.
37. Grosu AL, Weber W, Feldmann HJ, et al. First experience with I-123-alpha-methyl-tyrosine SPECT in the 3-D radiation treatment planning of brain gliomas. Int J Radiat Oncol Biol Phys 2000;47:517-26.
38. Grosu AL, Weber WA, Riedel E, et al. L-(Methyl-11C)-methionine positron emission tomography for target delineation in resected high grade gliomas before radiation therapy. Int J Radiat Oncol Biol Phys 2005 (in press).
39. Grosu AL, Weber WA, Franz M, et al. Re-irradiation for recurrent high grade glioma using amino-acids-PET(SPECT)/CT/MRI image fusion to determine gross tumore volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005 (in press).
40. Hanasono MM, Kunda LD, Segall GM, et al. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999;109:880-5.
41. Hannah A, Scott AM, Tochon-Danguy H, et al. Evaluation of 18F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002;236:208-17.
42. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990-5.
43. Hara T, Kosaka N, Shinoura N, et al. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 1997;38:842-7.
44. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v) beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5.
45. Hebert ME, Lowe VJ, Hoffman JM, et al. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 1996;19:416-21.
46. Heiss P, Mayer S, Herz M, et al. Investigation of transport mechanism and uptake kinetics of 0-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 1999;40:1367-73.
47. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low grade gliomas. Neurology 1998;50:1316-22.
48. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
49. Hofer C, Laubenbacher C, Block T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:31-5.
50. Iuchi T, Iwadate Y, Namba H, et al. Glucose and methionine uptake and proliferative activity in meningiomas. Neurol Res 1999;21:640-4.
51. Johansen J, Eigtved A, Buchwald C, et al. Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study. Laryngoscope 2002;112:2009-14.
52. Julow J, Major T, Emri M, et al. The application of image fusion in stereotactic brachytherapy of brain tumours. Acta Neurochir (Wien) 2000;142:1253-8.
53. Jungehulsing M, Scheidhauer K, Damm M, et al. 2[F]-fluoro-2-deoxy-D- glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000;123:294-301.
54. Kao CH, Shiau YC, Shen YY, et al. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99m methoxy-isobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission tomography. Cancer 2002;94:1981-6.
55. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778-85.
56. Kato T, Tsukamoto E, Kuge Y, et al. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002;29:1492-5.
57. Kau RJ, Alexiou C, Laubenbacher C, et al. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg 1999;125:1322-8.
58. Kiffer JD, Berlangieri SU, Scott AM, et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 1998;19:167-77.
59. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995;33:391-8.
60. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199-212.
61. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82: 1160-6.
62. Konishi J, Yamazaki K, Tsukamoto E, et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 2003;70:500-6.
63. Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27:1415-9.
64. Kotzerke J, Volkmer BG, Glatting G, et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003;42:25-30.
65. Kresnik E, Mikosch P, Gallowitsch HJ, et al. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med 2001;28:816-21.
66. Kunkel M, Grotz KA, Forster GJ, et al. Therapy monitoring with 2-(18F)-FDG positron emission tomography after neoadjuvant radiation treatment of mouth carcinoma. Strahlenther Onkol 2001;177:145-52.
67. Kuwert T, Morgenroth C, Woesler B, et al. Uptake of iodine-123-alpha- methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 1996;23:1345-53.
68. Langen KJ, Roosen N, Coenen HH, et al. Brain and brain tumor uptake of L-3-[123I]iodo-alpha-methyl tyrosine: competition with natural L-amino acids. J Nucl Med 1991;32:1225-9.
69. Langen KJ, Ziemons K, Kiwit JC, et al. 3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med 1997;38:517-22.
70. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7.
71. Lassen U, Daugaard G, Eigtved A, et al. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999;35:1076-82.
72. Lewis JS, Sharp TL, Laforest R, et al. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001;42:655-61.
73. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-60.
74. Liu RS. Clinical application of C11-acetate in oncology. Clin Positron Imaging 2000;3:185.
75. Lonneux M, Lawson G, Ide C, et al. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000;110:1493-7.
76. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000;18: 651-8.
77. Machulla HJ, ed. Imaging of hypoxia: tracer developments. Dordrecht: Kluwer Academic, 1999.
78. MacManus MP, Hicks RJ, Ball DL, et al. F-18-fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001;92:886-95.
79. MacManus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285-92.
80. Mah K, Caldwell CB, Ling YC, et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002;52:339-50.
81. Malyapa RS, Mutic S, Low DA, et al. Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer. Int J Radiat Oncol Biol Phys 2002;54:1140-6.
82. McGuirt WF, Williams DW 3rd, Keyes JW Jr, et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope 1995;105:373-5.
83. Menzel C, Dobert N, Hamscho N, et al. The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol 2004;180:497-501.
84. Mizowaki T, Cohen GN, Fung AY, et al. Towards integrating functional imaging in the treatment of prostate cancer with radiation: the registration of the MR spectroscopy imaging to ultrasound/CT images and its implementation in treatment planning. Int J Radiat Oncol Biol Phys 2002;54:1558-64.
85. Molls M. Tumor oxygenation and treatment outcome. In: Bokemeyer C, Ludwig H. Anemia in cancer. ESO Scientific Updates, vol 6. Amsterdam: Elsevier Science, 2001:175-87.
86. Molls M, Feldmann HJ, Fuller J. Oxygenation of locally advanced recurrent rectal cancer, soft tissue sarcoma and breast cancer. Adv Exp Med Biol 1994;345:459-63.
87. Molls M, Stadler P, Becker A, et al. Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol 1998;174:Suppl 4:13-6.
88. Molls M, Vaupel P. The impact of the tumor environment on experimental and clinical radiation oncology and other therapeutic modalities. In: Molls M, Vaupel P, eds. Blood perfusion and microenvironment of human tumors - implications for clinical radiooncology. Berlin-Heidelberg-New York: Springer, 2000:1-3.
89. Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59:913-8.
90. Mosskin MEK, Hindmarsh T, Holst H, et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol 1989;30:225-32.
91. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632-42.
92. Mueller-Lisse UG, Vigneron DB, Hricak H, et al. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 2001;221:380-90.
93. Munley MT, Marks LB, Scarfone C, et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer 1999;23:105-14.
94. Mutic S, Grigsby PW, Low DA, et al. PET-guided three-dimensional treatment planning of intracavitary gynecologic implants. Int J Radiat Oncol Biol Phys 2002;52:1104-10.
95. Mutic S, Malyapa RS, Grigsby PW, et al. PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes - a dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys 2003;55:28-35.
96. Nestle U, Walter K, Schmidt S, et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999;44:593-7.
97. Nishioka T, Shiga T, Shirato H, et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 2002;53:1051-7.
98. Nowak B, Di Martino E, Janicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999;38:312-8.
99. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-80.
100. Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 2000;48:43-52.
101. Nyberg G, Bergstrom M, Enblad P, et al. PET-methionine of skullbase neuromas and meningiomas. Acta Otolaryngol (Stockh) 1997;117:482-9.
102. Ogawa T, Shishido F, Kanno I, et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993;186:45-53.
103. Oyama N, Akino H, Kanamaru H, et al. [Fluorodeoxyglucose positron emission tomography in diagnosis of untreated prostate cancer.] Nippon Rinsho 1998;56:2052-5.
104. Oyama N, Akino H, Kanamaru H, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43:181-6.
105. Oyama N, Miller TR, Dehdashti F, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549-55.
106. Picchio M, Messa C, Landoni C, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F] fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337-40.
107. Piert M, Machulla HJ, Becker G, et al. Introducing fluorine 18-fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur J Nucl Med 1999;26:95-109.
108. Piert M, Machulla HJ, Becker G, et al. Dependency of the [18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol 2000;27:693-700.
109. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-13.
110. Pirzkall A, Li X, Oh J, et al. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 2004;59:126-37.
111. Pirzkall A, McKnight TR, Graves EE, et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 2001;50:915-28.
112. Rades D, Kuhnel G, Wildfang I, et al. Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001;12:1605-9.
113. Rahn AN, Baum RP, Adamietz IA, et al. [Value of 18F fluorodeoxyglucose positron emission tomography in radiotherapy planning of head-neck tumors.] Strahlenther Onkol 1998;174:358-64.
114. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 2001;218:776-82.
115. Ribom D, Engler H, Blomquist E, et al. Potential significance of (11)C-methionine PET as a marker for the radiosensitivity of low-grade gliomas. Eur J Nucl Med Mol Imaging 2002;29:632-40.
116. Riemann B, Konemann S, Popping D, et al. Early effects of irradiation on (123I)-IMT and (18F)-FDG uptake in rat C6 glioma cells. Strahlenther Onkol 2004;180:434-41.
117. Riemann B, Papke K, Hoess N, et al. Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine-123)-L-alpha- methyltyrosine SPECT. Radiology 2002;225:567-74.
118. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:535-42.
119. Roivainen A, Forsback S, Gronroos T, et al. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000;27:25-32.
120. Rose PG AL, Rodriguez M, Faulhaber PF, et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999;17:41-5.
121. Schmidt D, Gottwald U, Langen KJ, et al. 3-[123I]iodo-alpha-methyl-L- tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis. Eur J Nucl Med 2001;28:855-61.
122. Schmidt S, Nestle U, Walter K, et al. [Optimization of radiotherapy planning for non-small cell lung cancer (NSCLC) using 18FDG-PET.] Nuklearmedizin 2002;41:217-20.
123. Shibamoto Y, Tachi Y, Tanabe K, et al. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2′-deoxyuridine activated by hypoxic irradiation. Int J Radiat Oncol Biol Phys 2004;58:397-402.
124. Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996;199:751-6.
125. Spaepen K, Stroobants S, Verhoef G, et al. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003;30:Suppl 1:S97-105.
126. Stuckensen T, Kovacs AF, Adams S, et al. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 2000;28:319-24.
127. Sugawara Y, Eisbruch A, Kosuda S, et al. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 1999;40:1125-31.
128. Sweeney RA, Bale RJ, Moncayo R, et al. Multimodality cranial image fusion using external markers applied via vacuum mouthpiece and a case report. Strahlenther Onkol 2003;179:254-60.
129. Tinteren H van, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-93.
130. Tjuvajev JG, Chen SH, Joshi A, et al. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Res 1999;59:5186-93.
131. Umesaki N, Tanaka T, Miyama M, et al. Early diagnosis and evaluation of therapy in postoperative recurrent cervical cancers by positron emission tomography. Oncol Rep 2000;7:53-6.
132. Urtasun RC, Parliament MB, McEwan AJ, et al. Measurement of hypoxia in human tumours by non-invasive SPECT imaging of iodoazomycin arabinoside. Br J Cancer Suppl 1996;27:S209-12.
133. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000;55:317-24.
134. Voges J, Herholz K, Holzer T, et al. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg 1997;69:129-35.
135. Wagner M, Seitz U, Buck A, et al. 3′-[18F]fluoro-3′- deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003;63:2681-7.
136. Warburg OPK, Negelein E. The metabolism of cancer cells. Biochem Z 1924;152:129-69.
137. Weber W, Bartenstein P, Gross MW, et al. Fluorine-18-FDG PET and iodine 123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 1997;38:802-8.
138. Weber WA, Dick S, Reidl G, et al. Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. J Nucl Med 2001;42:1144-50.
139. Weber WA, Dietlein M, Hellwig D, et al. PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer. Nuklearmedizin 2003;42:135-44.
140. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-7.
141. Weber WA, Wester HJ, Grosu AL, et al. 0-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27:542-9.
142. Weckesser M, Griessmeier M, Schmidt D, et al. Iodine-123 alpha-methyl tyrosine single-photon emission tomography of cerebral gliomas: standardised evaluation of tumour uptake and extent. Eur J Nucl Med 1998;25:150-6.
143. Weckesser M, Matheja P, Rickert C, et al. Evaluation of the extension of cerebral gliomas by scintigraphy. Strahlenther Onkol 2000;176:180-5.
144. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000;164:400-4.
145. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001;219:316-33.
146. Woesler B, Kuwert T, Morgenroth C, et al. Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose. Eur J Nucl Med 1997;24:428-34.
147. Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001;28:117-22.
148. Zaider M, Zelefsky MJ, Lee EK, et al. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2000;47:1085-96.